Savara Inc.
NMS: SVRALive Quote
About Savara Inc.
Healthcare
Biotechnology
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
📊 Fundamental Analysis
Savara Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -63.4%, which indicates that capital utilization is currently under pressure.
At a current price of $5.66, SVRA currently sits at the 74th percentile of its 52-week range (Range: $1.89 - $7.00).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$1.01B
Trailing P/E
--
Forward P/E
-17.69
Beta (5Y)
0.31
52W High
$7.00
52W Low
$1.89
Avg Volume
1.63M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App